A Phase 3 interventional study of Metformin and control diet in Gestational Diabetes Mellitus, sponsored by Maasstad Hospital. Completed at 1 site in Netherlands. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Maasstad Hospital · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing metformin in Diabetes, Gestational — 4 open to participants now, 5 under way, none of them phase 3. Metformin · Diabetes, Gestational.
Among the 39 studies testing metformin in Diabetes, Gestational, this one is the 4th largest by planned enrollment, is one of 2 that started in 2014, is one of 12 in phase 3, and was the 20th registered.
878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.
Browse Diabetes, Gestational studies →4 of the 39 studies testing metformin in Diabetes, Gestational are open now, in 1 country. Recruiting first, the newest first:
University of Virginia · Sites in United States
Ages 18–50 · Women only
Anna Stanhewicz, PhD · Sites in United States
Ages 18–45 · Women only · Healthy volunteers
Ohio State University · Sites in United States
Ages 18+ · Women only
Assiut University
Ages 18–40 · Women only
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 40 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 16 · Phase 4 13
First in 2002; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 110 across 563 interventional studies indexed under Diabetes, Gestational.
Median enrollment 112 across the 39 interventional studies. Of the 23 that completed or were terminated, 7 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 39 has an industry lead sponsor. The 10 most frequent:
Maasstad Hospital is the lead sponsor of 21 studies on the registry; 5 are open to participants now.
Maasstad Hospital has 1 study filed under Diabetes, Gestational — fewer than ten, so there is no comparison to draw.
1 of the studies testing metformin in Diabetes, Gestational that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06948825George Washington UniversityEffectiveness Study of a Lifestyle Intervention Versus Metformin in Mothers With Recent Gestational Diabetes | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 39 studies testing metformin in Diabetes, Gestational, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Metformin vs Control to prevent gestational diabetes mellitus (GDM) in women with a high risk for GDM, an open label randomized controlled trial' The Medico-GDM trial
Rationale: GDM is a frequent pregnancy complication1 and associated with complications for mother and child.2 At present, the drug of choice for treatment of GDM is Insulin.3 In the last years several studies documented the use of oral blood glucose lowering medication in GDM. Metformin is an accepted alternative for insulin, with comparable glycemic control and neonatal outcomes.4 In studies with women with polycystic ovarian syndrome (PCOS) who received Metformin during pregnancy, the incidence of GDM is less compared to pregnant women with PCOS without Metformin. These studies were however small and there was no adequate control group.5 Our aim is to study the effect of Metformin on the incidence of GDM in women with a high risk for GDM.
Objective: the primary objective is to compare metformin versus no intervention for incidence of GDM in women with a high risk for GDM. The main secondary objective is pregnancy outcome with Metformin, neonatal outcomes and neonatal complications.
Study design: 2 years open label randomized controlled trial, comparing metformin versus control group.
Study population: pregnant women with a high risk of GDM between 18 and 40 years old in the first trimester of pregnancy.
Intervention: the first group receives Metformin twice daily 500 mg for the first week, after that twice daily 1000 mg. The second group receives no intervention. All the subjects are receiving a diet which contains a 2000 calories/day diet, with an adequate distribution of carbohydrates during the day.
Main study parameters/endpoints: the main study parameter is the difference in incidence of GDM between the two groups.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: the subjects will visit our centre for the first time between 12 and 14 weeks of pregnancy, then blood samples will be collected. Further on they will visit our centre at 24 weeks to perform an oral glucose tolerance test (OGTT). Women with GDM in history will perform an OGTT at 16 weeks for the first time. If the OGTT is borderline normal, it will repeated every 4 weeks. This is according to current Dutch guidelines3, without any extra discomfort for study participants. The subjects will visit their own gynaecologist or obstretican for their regular pregnancy controls. Metformin is not officially registered for use in pregnancy. Long term effects for the unborn child are not known. However, previous studies did not found neonatal and pregnancy related complications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
a subject must meet all of the following criteria:
Exclusion Criteria:
A potential subject who meets any of the following criteria will be excluded from participation in this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metformin twice daily 500 mg for the first week, after that twice daily 1000 mg. All the subjects are receiving a diet which contains a 2000 calories/day diet, with an adequate distribution of carbohydrates during the day.
Drug: Metformin · Other: control diet
a diet which contains a 2000 calories/day diet, with an adequate distribution of carbohydrates during the day.
Other: control diet
Metformin twice daily 500 mg for the first week, after that twice daily 1000 mg (from 14 weeks pregnancy untill delivery)
2000 calories/day diet, with an adequate distribution of carbohydrates during the day
incidence of gestational diabetes mellitus in both groups
Time frame: from 14 weeks pregnancy untill delivery
Maternal outcomes
Maternal: pregnancy induced hypertension (yes vs no: systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg), weight gain during pregnancy (kg), abnormal glucose daily curve after pregnancy (yes vs no: measurement of blood glucose concentration seven times daily).), insulin therapy required.
Time frame: from 14 weeks pregnancy untill delivery
Neonatal outcomes
head circumference (cm), birth weight (g) and height (cm), pH of umbilical-cord. Neonatal complications: serious neonatal complications (including: severe birth defects, stillbirth, birth trauma, respiratory distress, admission to neonatal intensive care unit, low 5-minutes Apgar score (\< 7) and premature birth (\< 37 weeks of gestation)), neonatal hypoglycaemia that requires therapy, need for phototherapy, small for gestational age (birth weight \< 2 SD units), birth weight \> 90th percentile, birth weight \< 10th percentile.
Time frame: from 14 weeks pregnancy untill delivery
Ran from Oct 2014 to primary completion in Mar 2017, 28 months.
Of 14 phase 3 interventional studies under Diabetes, Gestational, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 67. This study's 28 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: start Sep 2014 → Oct 2014, primary completion Sep 2016 → Mar 2017 and completion Sep 2017 → Mar 2017.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin
Maasstad Hospital